The Clinical Translation and Commercialization Medtech (CTCM) Programme, a Medical Research Future Fund (MRFF) initiative delivered by MTPConnect, will open its second round in September 2022.
The CTCM Program will provide funding between $250,000 to $1.5 million to accelerate eligible projects delivered over a maximum 24-month period.
To be considered for funding, projects must focus on the development of a medical device for human use, the purpose of which is to diagnose, prevent, monitor, treat or alleviate a disease or injury, or modify or monitor anatomy or physiological functions of the body.
Activities to be funded include, but are not limited to, prototype development and product testing, clinical trial activity and regulatory support.
MTPConnect Chief Executive Officer, Stuart Dignam, says this will be the final funding round of the CTCM programme, providing another opportunity for local innovators to be part of Australia’s growing medical products sector.
“In addition to financial support, applicants will be supported throughout the 24-month period with valuable educational support, consultation and access to critical engineering, fabrication and prototyping facilities to help accelerate translation of their medical device,” Dignam said.